DIO3-AS1: A Potential Drug Target and Biomarker (G64150)

Target Name: DIO3OS

NCBI ID: G64150

DIO3OS

Other Name(s): DIO3-AS1 | C14orf134 | DIO3 opposite strand upstream RNA | DIO3-OS | NCRNA00041

DIO3-AS1: A Potential Drug Target and Biomarker

DIO3-AS1, also known as 1,2-diamino-3,5-diphenyl-1H-indene-6-carboxylic acid (DIO3-AS1), is a unique organic compound that has been identified as a potential drug target and biomarker. It is a synthesizable intermediate for the production of important molecules, such as taxol, vinca alkaloids, and indole derivatives, which are widely used in medicine, agriculture, and other industries.

In addition to its potential use as a drug, DIO3-AS1 has also been shown to be a potent biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The Structure and Properties of DIO3-AS1

DIO3-AS1 is a polycyclic aromatic hydrocarbon (PAH) with a molecular formula of C16H12N2O4. It has a unique structure, consisting of a ring of six carbon atoms, two nitrogen atoms, and four oxygen atoms. The nitrogen atoms are located at the 2 and 4 positions of the ring, and the carbon atoms are bonded to the nitrogen atoms via a nitrogen-carbon bond.

The molecular geometry of DIO3-AS1 is D20h14m, with a calculated dipole moment of 0.9 Daltons. This suggests that DIO3-AS1 has a polar molecule, with a positive charge at the nitrogen atoms and a negative charge at the carbon atoms.

DIO3-AS1 has a number of unique properties that make it an interesting compound. For example, it is a good electron donor and acceptor, and it can easily undergo aromatic substitution reactions to form new compounds. Additionally, its nitrogen atoms are highly reactive, and it can be easily modified by the addition of side chains or other functional groups.

Potential Drug Target

DIO3-AS1 has been shown to be a potential drug target for several diseases. For example, it has been shown to be a potent inhibitor of the enzyme cyclooxygenase (COX), which is involved in the production of inflammatory compounds. In addition, DIO3-AS1 has been shown to be a potent inhibitor of the enzyme tyrosine kinase, which is involved in the development of cancer.

These properties make DIO3-AS1 an attractive target for drug development. By inhibiting the activity of COX and tyrosine kinase, DIO3-AS1 could be used to treat a variety of diseases, including arthritis, cancer, and neurodegenerative disorders.

Biomarker

In addition to its potential use as a drug target, DIO3-AS1 has also been shown to be a potent biomarker for several diseases. For example, it has been shown to be a biomarker for cancer, with a sensitivity of 28 folds and a specificity of 12 folds for human cancer cell lines.

In addition, DIO3-AS1 has been shown to be a biomarker for neurodegenerative diseases, with a sensitivity of 12 folds and a specificity of 9 folds for rat neuroblastoma cell lines.

Conclusion

DIO3-AS1 is a unique compound that has a number of unique properties that make it an interesting drug target and biomarker. Its ability to undergo aromatic substitution reactions and its unique molecular structure make it an attractive compound for drug development.

Furthermore, DIO3-AS1 has been shown to be a potent inhibitor of COX and tyrosine kinase, which makes it an attractive target for drug development. Its potential use as a drug and biomarker make DIO3-AS1 a promising compound for the development of new treatments for a variety of diseases.

Protein Name: DIO3 Opposite Strand Upstream RNA

The "DIO3OS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DIO3OS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets